F2G Ltd Secures $70 Million in Funding to Advance Groundbreaking Antifungal Therapies

F2G Ltd, a pioneering clinical-stage biopharmaceutical company specializing in innovative therapies for life-threatening invasive fungal infections, has successfully raised $70 million in funding to advance its groundbreaking research and development efforts. F2G is at the forefront of antifungal treatment innovation with its discovery of a novel class of antifungal agents known as orotomides. This unique class works by targeting fungal dihydroorotate dehydrogenase (DHODH), a crucial enzyme in the pyrimidine biosynthesis pathway, setting these therapies apart from conventional antifungal medications. The company’s flagship candidate, Olorofim (formerly F901318), exhibits potent fungicidal activity against a broad spectrum of mold infections, particularly those that are rare and resistant to existing treatments. Currently undergoing a Phase 2b open-label study, Olorofim aims to tackle a number of challenging invasive fungal infections, including azole-resistant invasive aspergillosis, coccidioidomycosis, and scedosporiosis, which represent significant unmet medical needs in the healthcare landscape. With its impressive regulatory designations, including orphan drug status from the European Medicines Agency and crucial FDA designations such as Breakthrough Therapy, F2G is positioned to make a meaningful impact in the fight against resistant fungal infections. The newly acquired funding will be instrumental in propelling Olorofim through clinical trials and towards market approval, with the ultimate goal of providing effective therapeutic solutions to patients facing these formidable infections. Headquartered in the UK, with subsidiaries in the US and Austria, F2G is committed to transforming the treatment landscape for invasive fungal infections, ensuring better outcomes for patients worldwide.